Evommune, Inc. (EVMN)
NYSE · Healthcare · Biotechnology
$6.65−3.90%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $241M
- 52-week range
- $6.52 – $33.20
- 52-week change
- −65.79%
- EPS (trailing)
- −$3.75
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Revenue
- $13.0M (+85.71%)
- Net income
- −$68.9M
- Operating margin
- −623.6%
- Diluted EPS
- −$11.22
- Free cash flow
- −$76.7M
From the company’s annual report on SEC EDGAR.
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Headquarters: Palo Alto, United States · 48 employees · evommune.com